Literature DB >> 16286408

Intravenous glycoprotein IIb/IIIa inhibitor (tirofiban) followed by intra-arterial urokinase and mechanical thrombolysis in stroke.

Salvatore Mangiafico1, Martino Cellerini, Patrizia Nencini, Gianfranco Gensini, Domenico Inzitari.   

Abstract

BACKGROUND AND
PURPOSE: The purpose of this study was to evaluate preliminarily the efficacy and safety of intravenous tirofiban combined with intra-arterial pharmacologic and mechanical thrombolysis in patients with stroke.
METHODS: Twenty-one consecutive patients with an acute ischemic stroke due to major cerebral arteries occlusion and a National Institutes of Health Stroke Scale [NIHSS] score > or = 18 were treated with an intravenous bolus of tirofiban and heparin followed by intra-arterial administration of urokinase coupled with mechanical thrombolysis.
RESULTS: Thirteen patients had an anterior circulation stroke (T-siphon internal carotid artery [ICA] = 7; middle cerebral artery [MCA] = 6), 6 patients a posterior circulation stroke, and 2 patients an anterior plus posterior circulation stroke (left ICA or M1 tract of MCA plus basilar artery occlusions). Mean NIHSS score on admission was 21 (range, 18-27). Immediate recanalization was successful (thrombolysis in myocardial infarction [TIMI] 2-3) in 17 of 21 patients. The following day, 14 of 19 patients improved substantially and complete vessel patency (TIMI 3-4) was confirmed by digital subtraction angiography. Intracranial bleeding occurred in 5 of 21 patients (3 symptomatic cerebral hemorrhages and 2 subarachnoid hemorrhages) and was fatal in the case of 3 patients. At discharge, the mean NIHSS was 5.4 (range, 0-25). Overall, at 3-month follow-up the functional outcome was favorable (modified Rankin Scale score = 0-2) in 13 of 21 (62%) patients. Death (including all causes) at 90 days occurred in 6 of 21 (28%) cases.
CONCLUSIONS: The combination of intravenous tirofiban with intra-arterial urokinase and mechanical thrombolysis may be successful in reestablishing vessel patency and result in a good functional outcome in patients with major cerebral arteries occlusions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16286408      PMCID: PMC7976211     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  25 in total

Review 1.  Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment.

Authors:  J E Tcheng
Journal:  Am Heart J       Date:  2000-02       Impact factor: 4.749

Review 2.  Molecular mechanisms of platelet activation.

Authors:  W Siess
Journal:  Physiol Rev       Date:  1989-01       Impact factor: 37.312

3.  Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score.

Authors:  P A Barber; A M Demchuk; J Zhang; A M Buchan
Journal:  Lancet       Date:  2000-05-13       Impact factor: 79.321

4.  Bleeding risk of tirofiban, a nonpeptide GPIIb/IIIa platelet receptor antagonist in progressive stroke: an open pilot study.

Authors:  U Junghans; R J Seitz; A Aulich; H J Freund; M Siebler
Journal:  Cerebrovasc Dis       Date:  2001       Impact factor: 2.762

5.  Acute basilar artery occlusion treated with combined intravenous Abciximab and intra-arterial tissue plasminogen activator: report of 3 cases.

Authors:  Bernd Eckert; Christoph Koch; Götz Thomalla; Joachim Roether; Herrmann Zeumer
Journal:  Stroke       Date:  2002-05       Impact factor: 7.914

6.  Use of abciximab for mediation of thromboembolic complications of endovascular therapy.

Authors:  H J Cloft; O B Samuels; F C Tong; J E Dion
Journal:  AJNR Am J Neuroradiol       Date:  2001-10       Impact factor: 3.825

7.  Changes in coagulation and fibrinolysis markers in acute ischemic stroke treated with recombinant tissue plasminogen activator.

Authors:  K Fassbender; C E Dempfle; O Mielke; A Schwartz; M Daffertshofer; C Eschenfelder; M Dollman; M Hennerici
Journal:  Stroke       Date:  1999-10       Impact factor: 7.914

8.  Intracerebral hemorrhages associated with neurointerventional procedures using a combination of antithrombotic agents including abciximab.

Authors:  Adnan I Qureshi; Mustafa Saad; Osama O Zaidat; Jose I Suarez; Michael J Alexander; M Fareed; K Suri; Zulfiqar Ali; L Nelson Hopkins
Journal:  Stroke       Date:  2002-07       Impact factor: 7.914

9.  Angioplasty after intra-arterial thrombolysis for acute occlusion of intracranial arteries.

Authors:  T Ueda; S Sakaki; I Nochide; Y Kumon; K Kohno; S Ohta
Journal:  Stroke       Date:  1998-12       Impact factor: 7.914

10.  Systemic thrombolysis with recombinant tissue plasminogen activator and tirofiban in acute middle cerebral artery occlusion.

Authors:  Stefan Straub; Ulrich Junghans; Verica Jovanovic; Hans J Wittsack; Rüdiger J Seitz; Mario Siebler
Journal:  Stroke       Date:  2004-01-29       Impact factor: 7.914

View more
  26 in total

Review 1.  Intravenous rt-PA versus endovascular therapy for acute ischemic stroke.

Authors:  Pitchaiah Mandava; Jose I Suarez; Thomas A Kent
Journal:  Curr Atheroscler Rep       Date:  2008-08       Impact factor: 5.113

2.  Safety of tirofiban for patients with acute ischemic stroke in routine clinical practice.

Authors:  Yuan-Qun Zhu; Yan-Jun Zhang; Hai-Lin Ruan; Qing Liu; Qin Zhan; Qiong Li
Journal:  Exp Ther Med       Date:  2015-05-15       Impact factor: 2.447

Review 3.  Platelet Glycoprotein IIb/IIIa Receptor Inhibitor Tirofiban in Acute Ischemic Stroke.

Authors:  Ming Yang; Xiaochuan Huo; Zhongrong Miao; Yongjun Wang
Journal:  Drugs       Date:  2019-04       Impact factor: 9.546

4.  Future trials of endovascular mechanical recanalisation therapy in acute ischemic stroke patients - a position paper endorsed by ESMINT and ESNR : part II: methodology of future trials.

Authors:  Jens Fiehler; Michael Söderman; Francis Turjman; Philip M White; Søren Jacob Bakke; Salvatore Mangiafico; Rüdiger von Kummer; Mario Muto; Christophe Cognard; Jan Gralla
Journal:  Neuroradiology       Date:  2012-09-05       Impact factor: 2.804

Review 5.  Targeting integrin and integrin signaling in treating thrombosis.

Authors:  Brian Estevez; Bo Shen; Xiaoping Du
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-09-25       Impact factor: 8.311

6.  Predictors of subarachnoid hemorrhage in acute ischemic stroke with endovascular therapy.

Authors:  Zhong-Song Shi; David S Liebeskind; Yince Loh; Jeffrey L Saver; Sidney Starkman; Paul M Vespa; Nestor R Gonzalez; Satoshi Tateshima; Reza Jahan; Lei Feng; Chad Miller; Latisha K Ali; Bruce Ovbiagele; Doojin Kim; Gary R Duckwiler; Fernando Viñuela
Journal:  Stroke       Date:  2010-11-04       Impact factor: 7.914

7.  Endovascular recanalization of acute intracranial vertebrobasilar artery occlusion using local fibrinolysis and additional balloon angioplasty.

Authors:  Junji Kashiwagi; Hiro Kiyosue; Yuzo Hori; Mika Okahara; Shuichi Tanoue; Yoshiko Sagara; Toshi Abe; Hiromu Mori
Journal:  Neuroradiology       Date:  2010-01-30       Impact factor: 2.804

8.  Intra-arterial adjuvant tirofiban after unsuccessful intra-arterial thrombolysis of acute ischemic stroke: preliminary experience in 16 patients.

Authors:  Jee-Hyun Kwon; Shang Hun Shin; Young Cheol Weon; Jae Cheol Hwang; Seung Kug Baik
Journal:  Neuroradiology       Date:  2011-08-02       Impact factor: 2.804

9.  Intra-arterial tissue plasminogen activator and abciximab in patients with acute basilar artery occlusion.

Authors:  A Chiti; G Gialdini; E Terni; N Giannini; M Gennaro; G A Lazzarotti; M Puglioli; G Orlandi; U Bonuccelli
Journal:  Neurol Sci       Date:  2013-05-24       Impact factor: 3.307

10.  Tirofiban combined with urokinase selective intra-arterial thrombolysis for the treatment of middle cerebral artery occlusion.

Authors:  Lei Feng; Jun Liu; Yunzhen Liu; Jian Chen; Chunhai Su; Chuanfeng Lv; Yuzhen Wei
Journal:  Exp Ther Med       Date:  2016-01-14       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.